Inventiva Shares Rise on Diabetes Treatment Trial Results

Dow Jones

Jan 23, 2025

By Katherine Hamilton

Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial.

The stock was up 15% to $2.50 after the market close on Wednesday.

The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint.

The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients.

The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 22, 2025 17:24 ET (22:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505070730"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505070730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505070730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505070730","market":"nz","top_or_hot":-1,"title":"Inventiva Shares Rise on Diabetes Treatment Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n</p>\n<p>\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n</p>\n<p>\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n</p>\n<p>\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n</p>\n<p>\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 17:24 ET (22:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventiva Shares Rise on Diabetes Treatment Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventiva Shares Rise on Diabetes Treatment Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-23 06:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n</p>\n<p>\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n</p>\n<p>\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n</p>\n<p>\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n</p>\n<p>\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 17:24 ET (22:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVA","symbol_name":"Inventiva S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505070730","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505070730","pubTimestamp":1737584640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial.The stock was up 15% to $2.50 after the market close on Wednesday.The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis , said a proof-of-concept trial met its primary efficacy endpoint.The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients.The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVA":"Inventiva S.A.","BK4139":"生物科技"},"translate_title":"Inventiva股价因糖尿病治疗试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n\n\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n\n\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n\n\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n\n\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 17:24 ET (22:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}